Ulcerative colitis
Conditions
Interventions
Oberservational group:Qingyu Powder
Control group:Vedolizumab, Infliximab
Sponsors
Shuguang Hospital affiliated to Shanghai University of traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) It conforms to the diagnostic criteria of UC western medicine and TCM syndrome differentiation criteria adopted in this study; (2) It conforms to the definition of moderate active period that is the improved Mayo score is between 6 and 10; (3) Must have definite endoscopic examination or histopathological examination within 3 months before intervention; (4) Age is 18~65 years old regardless of sex; (5) The medical records are between January 1 2021 and December 1 2024. (6) Sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with serious complications such as intestinal obstruction intestinal perforation gastrointestinal bleeding colorectal cancer etc. (2) Patients with serious primary diseases and infectious diseases of other organs; (3) There are cognitive impairment or mental illness and other diseases that affect the research results; (4) Pregnant or lactating women;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Histology-endoscopic mucosal remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Modified Mayo score;Integrals of TCM syndromes;Routine blood test; | — |
Countries
China
Contacts
Public ContactDou Danbo
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed